Abstract: A networking system comprising a plurality of content routers coupled to each other and to a plurality of providers and configured to route and cache content data, wherein the content routers are further configured to locate and route requested content to a user node coupled to the content routers, wherein the providers are configured to publish content and the content routers are further configured to receive and cache the content data in response to an interest request for content and to flood a content identifier for the content data to a plurality of neighboring content routers within a specified radius, wherein the content identifier enables the plurality of neighboring content routers to determine a nearest location from which to obtain the content data to enable efficient content routing.

Abstract: A networking system comprising an application service that runs on a cloud infrastructure and is configured to receive dual encrypted content from a content provider and re-encrypt the dual encrypted content to enable dynamic user group control for group-based user authorization, and a cloud storage service coupled to the application service and configured to store the dual encrypted content from the content provider and the re-encrypted dual encrypted content from the application service, wherein the application service and the storage service are configured to communicate and operate with a content delivery service that uses a content delivery network (CDN) to deliver the re-encrypted content to one or more users in a group authorized by the content provider.

Abstract: The present invention relates to 2?-allene-substituted nucleoside derivatives of the general formula (I): As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related ?-D and ?-L-nucleoside derivatives.

Abstract: A networking system comprising a virtual group controller in an information centric network configured to enable mobility and security for a plurality of users groups of the information centric network, a plurality of user groups coupled to the virtual group controller and associated with the users, a plurality of agents that are each associated with one of the user groups, and a database for trusted service profile coupled to the virtual group controller, wherein the virtual group controller is configured to interact with the agents to enable mobility for the user groups using a server-less domain-based naming scheme.

Abstract: A network component comprising a receiver configured to receive a signed content item and an associated security information from a publisher, wherein the security information indicates which group from a plurality of groups is allowed to access the signed content item, a storage unit configured to cache the content item and the associated security information, a processor to implement procedures to enforce security policies defined by the security information, and a transmitter configured to send the signed content item from the cache to a subscriber when the subscriber is a member of a group indicated by the security information as authorized to access the signed content item.

Abstract: The present invention relates to antiviral compounds of formula (I), compositions containing these compounds, processes for their preparation, intermediates in their synthesis, and their use as therapeutics for prevention of organ transplantation rejection, the treatment of immune disorders and inflammation, and treatment of viral (particularly hepatitis C viral) infection.

Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Abstract: The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

Abstract: System and method for specifying and implementing programs. A graphical program is created in a graphical specification and constraint language that allows specification of a model of computation and explicit declaration of constraints in response to user input. The graphical program includes a specified model of computation, a plurality of interconnected functional blocks that visually indicate functionality of the graphical program in accordance with the specified model of computation, and specifications or constraints for the graphical program or at least one of the functional blocks in the graphical program. The specified model of computation and specifications or constraints are useable to analyze the graphical program or generate a program or simulation.

Abstract: System and method for specifying and implementing programs. A graphical program is created in a graphical specification and constraint language that allows specification of a model of computation and explicit declaration of constraints in response to user input. The graphical program includes a specified model of computation, a plurality of interconnected functional blocks that visually indicate functionality of the graphical program in accordance with the specified model of computation, and specifications or constraints for the graphical program or at least one of the functional blocks in the graphical program. The specified model of computation and specifications or constraints are useable to analyze the graphical program or generate a program or simulation.

Abstract: An apparatus comprising a first content oriented network architecture (CONA) node configured to couple to at least one second CONA nodes and implement collaborative caching in accordance with criteria comprising at least one content caching objective and at least one network operational objective, wherein the content caching objectives are in accordance with the network operational objectives.

Abstract: An apparatus comprising a traffic engineering (TE) and server selection (SS) component configured to couple to an SS component and operate at a first time scale based on SS policies from the SS component, wherein the SS is configured to operate at a second timescale based on TE policies from the TE and SS component, and wherein the second timescale has a finer time granularity than the first time scale by at least one order of magnitude. Also disclosed is a network component comprising a receiver configured to receive one or more SS policies from a content provider or customer node, a logic circuit configured to compute a plurality of joint TE and SS policies for a plurality of network nodes based on the received SS policies, and a transmitter configured to send the joint TE and SS components to the content provider or customer node.

Abstract: The present invention relates to antiviral compounds of formula (I), compositions containing these compounds, processes for their preparation, intermediates in their synthesis, and their use as therapeutics for prevention of organ transplantation rejection, the treatment of immune disorders and inflammation, and treatment of viral (particularly hepatitis C viral) infection.

Abstract: The present invention provides antiviral compounds of formula (I), as well as pharmaceutical compositions comprising these compounds, methods for synthesizing these compounds and methods of using these compounds for treating a viral infection.

Abstract: A teaching apparatus for enterprise input-output includes a base, said base defining a market system; a first block body defining a management module; a plurality of bands defining a production system and a product development system module, and a business system module, each band being sandwiched between two adjacent cuboids of the first block body; a vertical column defining a planning system module; a second block body defining a strategy module; a reverse quadrangle cone defining an information processing module; a cuboid vertical column disposed at a top of the reverse quadrangle cone; and a core solid column defining an internal information system, the core solid column penetrating through a center of the first block body, the bands, the vertical column, the second block body, the reverse quadrangle cone, and the cuboid vertical column.

Abstract: The present invention discloses compounds of formula Ia or Ib or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention provides novel proline substituted cyclosporinanalogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.

Abstract: The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.